By targeting the CD80 and CD86 molecules through CTLA-4 chimera proteins, both abatacept and belatacept became the earliest approved treatments against various autoimmune diseases, including rheumatic arthritis and juvenile idiopathic arthritis [13,14]. The gene discussed is CTLA4; the disease is autoimmune disease.